25
Participants
Start Date
September 14, 2018
Primary Completion Date
September 15, 2021
Study Completion Date
September 15, 2021
Biktarvy
Open-label, multicenter, single-arm study to Evaluate the Safety and Efficacy of Switching from Regimens Consisting of Abacavir/Lamivudine/Dolutegravir (ABC/3TC/DTG) to the Bictegravir/ Emtricitabine/Tenofovir Alafenamide (B/F/TAF) Fixed-Dose Combination (FDC) in Virologically-Suppressed HIV-Infected Adult Subjects
Tufts Medical Center, Boston
Brigham and Women's Hospital, Boston
Boston Medical Center, Boston
Collaborators (1)
Tufts Medical Center
OTHER
Boston Medical Center
OTHER
Brigham and Women's Hospital
OTHER